Egfr binding proteins and methods of use
AssigneeHarpoon Therapeutics, Inc.
InventorsHolger WESCHE, Richard J. AUSTIN
Life of this patent
Estimating the term…
Abstract
Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
Claims21
1-68. (canceled)
An EGFR binding protein comprising:
- (a) a complementarity determining region 1 (CDR1), wherein the CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 50-98;
- (b) a complementarity determining region 2 (CDR2), wherein the CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 99-147;
- and
- (c) a complementarity determining region 3 (CDR3), wherein the CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 148-196.
Dependencies are inferred from the claim text.